Ludovica Gaiaschi

Dr. Ludovica Gaiaschi

Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, Pavia, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Ludovica GaiaschiLudovica Gaiaschi
Ludovica Gaiaschi
Maria Grazia BottoneMaria Grazia Bottone
Maria Grazia Bottone
FLFabrizio De Luca
Fabrizio De Luca
Glioblastoma multiforme (GBM) is one of the most aggressive and difficult-to-treat brain tumors, with a poor prognosis due to its high resistance to conventional therapies. Current treatment options, including surgical resection, radiotherapy, and chemotherapy, have limited effectiveness in improving long-term survival. Despite the emergence of new therapies, monotherapy approaches have not shown significant improvements, highlighting the need for innovative therapeutic strategies. Combination therapies appear to be the most promising solution, as they target multiple molecular pathways involved in GBM progression. One area of growing interest is the incorporation of phytotherapy and micotherapy as complementary treatments, which offer potential benefits due to their anti-tumor, anti-inflammatory, and immunomodulatory properties. This review examines the current challenges in GBM treatment, discusses the potential of combination therapies, and highlights the promising role of phytotherapy and micotherapy as integrative therapeutic options for GBM management.

Verified
Journal Article
Open access
PDF file
Ludovica GaiaschiLudovica Gaiaschi
Ludovica Gaiaschi
FLFabrizio De Luca
Fabrizio De Luca
ERElisa Roda
Elisa Roda
BFBeatrice Ferrari
Beatrice Ferrari
CCClaudio Casali
Claudio Casali
Maria Grazia BottoneMaria Grazia Bottone
Maria Grazia Bottone
The current standard oncotherapy for glioblastoma is limited by several adverse side effects, leading to a short-term patient survival rate paralleled by a worsening quality of life (QoL). Recently, Complementary and Integrative Medicine’s (CIM) innovative approaches have shown positive impacts in terms of better response to treatment, side effect reduction, and QoL improvement. In particular, promising potential in cancer therapy has been found in compounds coming from phyto- and mycotherapy. The objective of this study was to demonstrate the beneficial effects of a new phyto-mycotherapy supplement, named Ganostile, in the human glioblastoma cell line U251, in combination with chemotherapeutic agents, i.e., Cisplatin and a new platinum-based prodrug. Choosing a supplement dosage that mimicked oral supplementation in humans (about 1 g/day), through in vitro assays, microscopy, and cytometric analysis, it has emerged that the cells, after 48hr continuous exposure to Ganostile in combination with the chemical compounds, showed a higher mortality and a lower proliferation rate than the samples subjected to the different treatments administered individually. In conclusion, our data support the use of Ganostile in integrative oncology protocols as a promising adjuvant able to amplify conventional and new drug effects and also reducing resistance mechanisms often observed in brain tumors.

24 September 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Ludovica GaiaschiLudovica Gaiaschi
Ludovica Gaiaschi
ERElisa Roda
Elisa Roda
CFCristina Favaron
Cristina Favaron
FGFederica Gola
Federica Gola
Elisabetta GabanoElisabetta Gabano
Elisabetta Gabano
Maria Grazia BottoneMaria Grazia Bottone
Maria Grazia Bottone
Glioblastoma (GBM) is the most common and mortal primary brain tumor in human. After standard therapies, that include surgical resection followed by radiotherapy and chemotherapy, it is difficult to completely remove the tumor and the development of relapses and resistance is almost inevitable. The chemotherapy now available also show important side effects, to overcame those limitation, new platinum-based drugs are being synthetized, Pt(IV)Ac-POA, (OC-6-44)-acetate-diamine-chloride(2-(2-propynyl)octanoato)platinum(IV), a prodrug having an Histone-3-DeAcetylase-Inhibitor as axial ligands, is one of them. Moreover, new compounds of plant origin are increasingly seen as potential sources of benefits in oncological treatments. The aim of the study is to investigate the possible contribution of micotherapy in the fight against GBM, its role in the metabolism of reactive oxygen species (ROS) and its synergic effect with a new platinum-based compound, Pt(IV)Ac-POA, on human glioblastoma U251 cells. Through cytofluorimetric and immunofluorescence analysis, the ability of the micotherapy in study to regulate the cell cycle was assessed, and its importance in controlling the cellular redox state was also revealed, opening to the possibility of a new therapy in which micotherapy can support the activity of new chemotherapy while reducing its side effects controlling inflammatory conditions in the microenvironment. Additionally, the combined therapy appeared able to induce regulated form of necrosis, such as ferroptosis, and to hinder the establishment of resistance mechanisms.

27 May 2023 in Apoptosis
Verified
Journal Article
Open access
PDF file
Ludovica GaiaschiLudovica Gaiaschi
Ludovica Gaiaschi
CFCristina Favaron
Cristina Favaron
CCClaudio Casali
Claudio Casali
FGFederica Gola
Federica Gola
FLFabrizio De Luca
Fabrizio De Luca
Maria Grazia BottoneMaria Grazia Bottone
Maria Grazia Bottone
Malignant primary brain tumors remain among the most difficult cancers to treat, in particular, Glioblastoma Multiforme (GBM) is the deadliest brain tumor. The standard therapies currently used are not efficient enough in improving patients’ survival and quality of life. Cisplatin (CDDP), a platinum-based drug, has shown efficacy against different solid neoplasms, but it is also associated to different forms of off-target toxicity. To overcome the limitation in the use of CDDP in the treatment of GBM patients, fourth generation platinum compounds are been synthesized, one of them is the Pt(IV)Ac-POA, a prodrug with a medium-chain fatty acid as axial ligand, which acts as a histone 3 deacetylase inhibitor. Moreover, recently, the antioxidant effects of medicinal mushrooms have been shown to induce a lowering of the toxicity of chemotherapy drugs, inducing greater therapeutic efficiency, thus the combined therapy of chemotherapy and micotherapy could be helpful in the treatment of GBM reducing the adverse effects of the former thanks to phytotherapy’s antioxidant, anti-inflammatory, immunomodulatory and antitumoral activities. Here, through immunoblotting, ultrastructural and immunofluorescence analysis, we evaluated the contribution in the activation of different cell death pathway of Micotherapy U-Care, a medicinal blend supplement, used together with platinum-based compounds on human glioblastoma U251 cells.

6 September 2023 in Molecules
Verified
Journal Article
Open access
PDF file
CFCristina Favaron
Cristina Favaron
Elisabetta GabanoElisabetta Gabano
Elisabetta Gabano
IZIlaria Zanellato
Ilaria Zanellato
Ludovica GaiaschiLudovica Gaiaschi
Ludovica Gaiaschi
CCClaudio Casali
Claudio Casali
Mauro RaveraMauro Ravera
Mauro Ravera
The effects of ferrocene (Fc) and ferrocenium (Fc+) induced in triple negative human breast cancer MCF-7 cells were explored by immunofluorescence, flow cytometry, and transmission electron microscopy analysis. The different abilities of Fc and Fc+ to produce reactive oxygen species and induce oxidative stress were clearly observed by activating apoptosis and morphological changes after treatment, but also after tests performed on the model organism D. discoideum, particularly in the case of Fc+. The induction of ferroptosis, an iron-dependent form of regulated cell death driven by an overload of lipid peroxides in cellular membranes, occurred after 2 h of treatment with Fc+ but not Fc. However, the more stable Fc showed its effects by activating necroptosis after a longer-lasting treatment. The differences observed in terms of cell death mechanisms and timing may be due to rapid interconversion between the two oxidative forms of internalized iron species (from Fe2+ to Fe3+ and vice versa). Potential limitations include the fact that iron metabolism and mitophagy have not been investigated. However, the ability of both Fc and Fc+ to trigger different and interregulated types of cell death makes them suitable to potentially overcome the shortcomings of traditional apoptosis-mediated anticancer therapies.

27 January 2025 in Cell Proliferation
Verified
Journal Article
Open access
Ludovica GaiaschiLudovica Gaiaschi
Ludovica Gaiaschi
CCClaudio Casali
Claudio Casali
ASAndrea Stabile
Andrea Stabile
SDSharon D'AMico
Sharon D'AMico
Mauro RaveraMauro Ravera
Mauro Ravera
MBMaria Grazia Bottone
Maria Grazia Bottone
Due to the lack of effective therapeutic approach, glioblastoma (GBM) remains one of the most malignant brain tumour. By in vitro investigations on primary GBM stem cells, we highlighted one of the underlying mechanisms of drug resistance to alkylating agents, the DNA damage responses. Here, flow cytometric analysis and viability and repopulation assays were used to assess the long‐term cytotoxic effect induced by the administration of a fourth‐generation platinum prodrug, the (OC‐6‐44)‐acetatodiamminedichlorido(2‐(2‐propynyl)octanoato) platinum(IV) named Pt(IV)Ac‐POA, in comparison to the most widely used Cisplatin. The immunofluorescence studies revealed changing pathways involved in the DNA damage response mechanisms in response to the two chemotherapies, suggesting in particular the role of Poly (ADP‐Ribose) polymerases in the onset of resistance to Cisplatin‐induced cytotoxicity. Thus, this research provides a proof of concept for how the use of a prodrug which allows the co‐administration of Cisplatin and an Histone DeACetylase inhibitors, could suppress DNA repair mechanisms, suggesting a novel effective approach in GBM treatment.